V Convención de la Profesión Médica

V Convención de la Profesión Médica • El Said M, Kapczynski A. Access to medicines: The role of intellectual property law and policy. Working Paper prepared for the Third Meeting of the Technical Advisory Group of the Global Commission on HIV and the Law, 7-9 July 2011. • Emanuel EJ, Fuchs VR. The perfect storm of overutilization. JAMA. 2008;299(23):2789-91. • European Commission. European Competition Pharmaceutical Sector Inquiry. 2009. Even P, Debré B. Guide des 4,000 médicaments utiles, inutiles ou dangereux. Collection Documents. Cherche Midi. 2012. • EXPH. Preliminary Report on Access to Health Services in the European Union. Expert Panel on Effective ways of investing in Health. September 2015. http://ec.europa.eu/health/expert_panel/opinions/docs/010_access_healthcare_en .pdf • Farmaindustria. Memoria anual 2014. 2015. • Flacco ME, Manzoli L, Boccia S, Capasso L, Aleksovska K, Rosso A, et al. Head-to- head randomized trials are mostly industry sponsored and almost always favour the industry sponsor. J Clin Epidemiol. 2015;68(7):810-20. • Forbes. The World’s Biggest Public Companies 2015 Ranking. 2015. http://www.forbes.com/global2000/ list/#tab:overall. • Franklin C. America’s epidemic of over-prescribing. The Guardan. 20 June 2011. • Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for providing Hepatitis C Direct Acting Antivirus for use in large-scale treatment access programs in developing countries. Clinical Infectious Diseases. 2014;58:928-36. • Holloway KA. Combating inappropriate use of medicines. Expert Rev Clin Pharmacol. 2011;4(3):335-48. House of Commons Health Committee. The influence of the pharmaceutical industry. 2005. http://www. parliament.the-stationery- office.co.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf. • Kapczynski A, Kesselheim AS. Government patent use”: a legal approach to reducing drug spending. Health Affairs. 2016;35:791-7.